Cutaneous T Cell Lymphoma Clinical Trial
Official title:
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma
Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.
Trial Subjects (patients) who are deemed eligible for the trial will be administered a single infusion of pembrolizumab (200mg) every 3 weeks. At week 12, patients will be planned to start radiotherapy at a dose of 12 Gray (Gy) in 3 fractions which will be given concomitantly with pembrolizumab. Patients who progress on pembrolizumab before week 12 will start radiotherapy as soon as possible after progression. Following completion of radiotherapy, patients will continue receiving pembrolizumab at 3 weekly intervals for a maximum of 2 years until disease progression or unacceptable toxicity develops. Patients on pembrolizumab will be seen every 3 weeks until 2 years after study entry, while Patients who progressed/ stopped pembrolizumab will be seen annually for survival/disease status only. Patients completing 2 years of treatment will then be followed up annually for survival and disease status until the end of trial is declared (2 years after the last patient is registered). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02546440 -
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
|
Phase 2 | |
| Recruiting |
NCT04014374 -
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
|
||
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Active, not recruiting |
NCT01460914 -
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
|
||
| Completed |
NCT04955340 -
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
|
Phase 1 | |
| Recruiting |
NCT02539472 -
Early Diagnosis of Mycosis Fungoides
|
N/A | |
| Recruiting |
NCT06436677 -
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
|
||
| Recruiting |
NCT05680558 -
Photopheresis in Early-stage Mycosis Fungoides
|
Phase 2 | |
| Recruiting |
NCT01132989 -
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05414500 -
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
|
Phase 1 | |
| Terminated |
NCT01663571 -
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
|
||
| Active, not recruiting |
NCT02192021 -
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
|
Phase 1 | |
| Recruiting |
NCT05781386 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02576496 -
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
| Withdrawn |
NCT03235869 -
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
|
Early Phase 1 | |
| Active, not recruiting |
NCT01396070 -
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
|
N/A | |
| Completed |
NCT01198665 -
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03932279 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
|
||
| Not yet recruiting |
NCT05728879 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
|
Early Phase 1 |